WO2005018656A1 - 脳神経細胞死予防及び/または改善剤 - Google Patents
脳神経細胞死予防及び/または改善剤 Download PDFInfo
- Publication number
- WO2005018656A1 WO2005018656A1 PCT/JP2004/011037 JP2004011037W WO2005018656A1 WO 2005018656 A1 WO2005018656 A1 WO 2005018656A1 JP 2004011037 W JP2004011037 W JP 2004011037W WO 2005018656 A1 WO2005018656 A1 WO 2005018656A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- ameliorating
- extract
- cell death
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to a prophylactic and / or ameliorating agent for cerebral nerve cell death and / or an agent for preventing and / or ameliorating Alzheimer's disease, comprising an extract of a wolfberry plant as an active ingredient, and an agent for preventing and / or ameliorating cerebral neuronal cell death or an Alzheimer's disease
- the present invention relates to a food or drink containing an agent for preventing and / or improving a disease.
- Alzheimer's disease is a slow but constantly progressive neurodegenerative disease with clinical symptoms centering on dementia characterized by memory loss and cognitive dysfunction.
- amyloid 3 protein A / 3
- amyloid 8 protein A j3 is important as a substance that induces neuronal cell death in the brain in Alzheimer's disease.
- the amyloid 3 protein is formed by cleaving its precursor protein with a protease called j3 secretase, and further cleaving it with 7 secretase.
- Presenilin an enzyme involved in the production of ⁇
- ⁇ -selectase a protease required for the production of ⁇ .
- vaccine therapy using ⁇ -amyloid as an antigen cf. Chen, G. et al., ature, 408, 975-979, 2000.
- Possibilities are being considered.
- neurodegenerative diseases such as Alzheimer's disease, oxidative stress has been implicated in the pathology, and oxidative stress in living tissue is an oxidative stress marker.
- abnormal cell aggregates such as A in Alzheimer's disease, intranuclear inclusions caused by polyglutamine in Huntington's disease, and ⁇ _synuclein in Parkinson's disease may also cause neuronal cell death in neurodegenerative diseases.
- a in Alzheimer's disease intranuclear inclusions caused by polyglutamine in Huntington's disease
- ⁇ _synuclein in Parkinson's disease may also cause neuronal cell death in neurodegenerative diseases.
- Lycium plants are plants of the Solanaceae family, and include species such as Lycium chinensis, Lycium barbarum, Lycium turcomanicum, Lycium potaninn, and Lycium dasystemum.
- the leaves are called lycopodium leaves, the fruits are called lycopodium, and the root bark is called skeletal bark. It is said to enhance liver function, hypertension, atherosclerosis, prevent presbyopia, etc., and in addition to carotene 'vitamines,] 3 sitosterol Contains linoleic acid, zeaxanthin and betaine-fezaliene.
- An object of the present invention is to provide an agent for preventing and / or improving brain nerve cell death or an agent for preventing and / or improving Alzheimer's disease from a safe food material or an extract thereof.
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems.
- the extract obtained by contacting the wolfberry plant material with water or a mixed solvent mainly composed of water yielded an extract of cerebral nerve cells.
- the present inventors have found that the compound has a prophylactic and / or ameliorating effect or a prophylactic and / or ameliorating effect on Alzheimer's disease, and has completed the present invention.
- the first aspect of the present invention relates to a preventive and / or ameliorating agent for cerebral nerve cell death, comprising a Lycium plant material or an extract therefrom as an active ingredient.
- a preventive and / or ameliorating agent for cerebral nerve cell death comprising a Lycium plant material or an extract therefrom as an active ingredient.
- the present invention relates to a preventive and / or ameliorating agent for Alzheimer's disease comprising a plant material or an extract therefrom as an active ingredient.
- the method for producing Lycium plants used in the present invention is not particularly limited.
- the wolfberry plant used in the present invention may be not only a naturally grown plant but also an artificially cultivated plant.
- wolfberry plant used in the present invention only one kind may be selected from those produced by various production methods, or a plurality of species may be used in combination.
- a Lycium chinensis plant is used.
- the extract is obtained by extracting various parts of the plant body (whole plant, flower, leaf, etc.) as they are or after pulverizing them and extracting them with an extraction solvent. Further, they can be used in combination with each solvent extract.
- the extraction solvent water or a mixed solvent mainly composed of water can be used.
- the water-based mixed solvent referred to in the present invention is mainly composed of water (water content is about 21% or more, preferably about 31% or more, more preferably about 41% or more, and most preferably about 5% or more. 1% or more), and a polar organic solvent such as an alcohol (for example, a lower alcohol such as ethanol or methanol, or a polyhydric alcohol such as glycerin) alone or in any combination of two or more liquids. .
- the amount of the water-based mixed solvent used for the extraction is such that the water content is about 51% or more from the viewpoint of improving the extraction efficiency of the active ingredient contained in the wolfberry plant material. It is preferable to use an amount capable of sufficiently dissolving.
- the components to be extracted are different because the polarity as the solvent is different compared to when mainly extracted with an organic solvent.
- hot water When water is used as the extraction solvent, it is preferable to use hot water from the viewpoint of improving the extraction efficiency of the active ingredient contained in the wolfberry plant material.
- the amount of hot water used for the extraction is preferably an amount capable of sufficiently dissolving the active ingredient contained in the wolfberry plant material.
- the production method is not particularly limited, except for the type of the extraction solvent.
- the extraction may be carried out using an extraction solvent at normal temperature and normal pressure, and after the extraction, the solution may be concentrated to dryness or oil or fat. It may be in the form of paste, paste, gel, or powder.
- the extraction temperature can be, for example, from about 0 to 100 ° C, about 30 to 100 ° C, or about 60 to 100 ° C. In some cases, extraction under conditions of about 30 to 120 ° C, and extraction under supercritical conditions using autoclave, carbon dioxide, etc. are also possible.
- the extraction time can be, for example, about 30 minutes to about 10 days, about 1 hour to 5 days, or about 2 hours to 1 day.
- the amount of the extraction solvent may be, for example, about 1 to 100 parts by weight, about 2 to 100 parts by weight, or about 5 to 50 parts by weight, based on 1 part by weight of the wolfberry plant material. .
- the collected wolfberry material is washed to remove dirt and organisms attached to the surface, and then crushed by cutting, pole mill, ultrasonic treatment, homogenizer, etc., and then extracted. it can. Prior to crushing, air drying or freeze drying may be performed.
- the crushed wolfberry plant material is preferably extracted several times with an extraction solvent such as hot water while stirring.
- This extract can be used as it is as an agent for preventing and / or improving brain nerve cell death or an agent for preventing and / or improving Alzheimer's disease.
- the invention also relates to a method for preventing and / or ameliorating said condition in a mammal.
- the extract of the present invention can be adjusted to an appropriate concentration by diluting or concentrating as necessary. Further, by spray-drying the extract, a preventive and / or ameliorating agent for powdery neuronal cell death or prevention and / or prevention of Alzheimer's disease can be obtained. It can also be an improver. As described above, the concentration and shape of the extract of the present invention are not particularly limited, and can be appropriately determined according to the use.
- the extract of the present invention can also be used as an orally or non-orally ingestible composition containing components other than an extract of a wolfberry plant material.
- the composition can be used in foods and drinks, or pharmaceuticals, cosmetics, and baths to which other nutrients or active ingredients are added as long as the effect of wolfberry is not reduced.
- the extract of the present invention is highly safe for living organisms because the extract of edible genus moss plant material is used as an active ingredient. Therefore, the extract of the present invention can be contained in a wide range of products such as pharmaceuticals, functional foods, foods and drinks, quasi-drugs, cosmetics, and bath preparations.
- the preventive and / or ameliorating agent for cerebral nerve cell death is preferably an agent for preventing and / or ameliorating a neurodegenerative disease, more preferably an agent for preventing and / or ameliorating Alzheimer's disease.
- Neurodegenerative diseases can include, but are not limited to, Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal or subcortical dementia of blood vessels or other progeny.
- the agent for preventing and / or ameliorating brain nerve cell death or the agent for preventing and / or ameliorating Alzheimer's disease comprises an extract as an active ingredient, and may be an extract or an extract itself, or a known agent. It may be a composition to which carriers, auxiliaries, food and drink materials, other pharmaceutically acceptable formulation materials, etc. are added.
- concentration of the extract can be appropriately selected within a range in which a desired effect is exhibited, and the dose to be administered to the human body is, for example, about 0.01 to 50 mg / kg body weight per day.
- the drug can be administered in one to several doses, depending on the purpose and route of administration of the drug, depending on the purpose, route of administration, tablets, capsules, injections, drops, powders, suppositories, Granules, ointments, It can be made into turbidity, emulsion, syrup, cream, etc.
- binders, excipients, lubricants, disintegrants, stabilizers, emulsifiers generally used in pharmaceutical preparations And additives such as buffering agents, etc.
- Preferred examples of the binder include guar gum, acacia powder and the like.
- Preferred examples of excipients include starch, trehalose, dextrin and the like.
- Preferred examples of the lubricant include stearic acid, talc, sucrose fatty acid ester, polyethylene glycol and the like.
- Preferable examples of the disintegrant include starch, carboxymethylcellulose, corn starch and the like.
- Preferred examples of the stabilizer include fats and oils, propylene glycol, cyclodextrin and the like.
- Preferable examples of the emulsifier include an anionic surfactant, a nonionic surfactant, and polybutyl alcohol.
- Preferred examples of the buffer include buffers such as phosphate, carbonate, and citrate.
- the extract of the present invention can be contained in foods and drinks, cosmetics and bath preparations.
- the content thereof is, for example, usually about 0.0001 to 100% by weight as food or drink, and about 0.1 to 100% by weight in view of the fact that it can be ingested efficiently.
- About 100% by weight, usually about 0.0001% by weight or more as a bath agent, and about 0.001% to 100% by weight is preferable because it can be efficiently mixed.
- the extract of the present invention when contained in cosmetics and used as a preventive and / or ameliorating agent for cerebral nerve cell death or as a preventive and / or ameliorating agent for Alzheimer's disease, it can be efficiently incorporated at about 0.0001% by weight or more. , About 0.01 to 20 weight. /. It is preferred that
- the extract of the present invention has a preventive and / or ameliorating effect on cerebral nerve cell death and / or a preventive and / or ameliorating effect on Alheimer's disease, by including it in food, the extract can prevent and / or prevent cerebral nerve cell death.
- it can be a functional food for the purpose of improvement or prevention and / or improvement of Alzheimer's disease.
- the kind of the food to be targeted is not particularly limited as long as the extract does not inhibit the preventive and / or ameliorating effect of the cerebral nerve cell death or the preventive and / or ameliorating effect of Alzheimer's disease.
- seasonings such as mirin, sprinkles, and miso.
- wolfberry can be crushed as it is, and it can be added directly to food etc., and even if the crushed material is ingested directly, It is presumed that the active ingredient of the wolfberry plant material is extracted by ingested water or digestive fluid in the body.
- the extract of the wolfberry plant material of the present invention has a neuronal cell death inhibitory action by an amyloid protein which is an Alzheimer's disease-causing substance, it is an agent for preventing and / or ameliorating brain neuronal cell death or preventing and / or ameliorating Alzheimer's disease. Useful as an agent.
- the present invention can improve the quality of life by preventing or delaying the progress of symptoms mainly by preventing and / or improving neurodegenerative death due to oxidative stress of brain nerve cells, and improving the quality of life simply. It is not intended to improve learning ability or memory.
- Amyloid protein a causative substance of Alzheimer's disease, deposits in nerve cells in the brain and generates radicals and the like, causing cell damage and cell death.
- a common mechanism of neurodegenerative diseases is caused by accumulation of abnormal proteins, for example, amyloid protein in Alzheimer's disease and polyglutamine in Huntington's disease.
- the anti-neural cell death evaluation performed in the present invention revealed that the extract of the wolfberry plant material had a cytoprotective effect on amyloid protein.
- Anti-neuronal cell death evaluation involves, for example, adding a sample extract to human neuroblastoma cell line SH-SY5Y cells, adding amyloid J3 protein, a causative agent of Alzheimer's disease, culturing the cells, and then measuring the number of viable cells. Is possible.
- the number of viable cells can be easily measured, for example, by a protein quantification method using 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2Htetrazolium bromide (MTT). be able to.
- the anti-neural cell death evaluation or the anti-Alzheimer effect can be evaluated by measuring the number of viable cells after completion of the culture using the above-described evaluation system. That is, the number of viable cells after the above operation is larger when the plant extract sample has a cytoprotective effect, as compared with the control without the plant extract sample.
- the relative viability which indicates the ratio of the number of viable cells in the plant extract sample-treated group to the plant extract-untreated group, exceeds about 1.0 This indicates that the plant extract sample has a preventive and / or ameliorating effect on brain nerve cell death or a preventive and / or ameliorating effect on Alzheimer's disease.
- FIG. 1 shows the results of evaluating anti-neural cell death using human neuroblastoma cell line SH-SY5Y cells.
- Lycium chinensis Plant material 1 g of dry weight was cut and crushed. They were placed in ethanol and left in a dark place out of direct sunlight for 4 weeks. After centrifugation at 3000 rpm at 4 ° C for 5 minutes, the supernatant was filtered through a 0.22 ⁇ m filter to obtain a 70% ethanol extract sample.
- Lycium chinensis (Lycium chinensis) plant material was cut and crushed, 10 L of water was added, and autoclaving was performed at 105 ° C for 15 minutes. The mixture was centrifuged at 3000 rpm at 4 ° C for 5 minutes, and the supernatant was filtered through a 0.22 ⁇ m filter to obtain an extract. The obtained liquid was concentrated to dryness to obtain about 87 g of a solid.
- Example 1 Evaluation of anti-neural cell death 15% FBS, DMEM / Ham's F-12 (1: 1 mixture) 1% non-essential MEM amino acid, 1% penicillin (SOOO ⁇ ug / ml)-Streptomycin (5000 IU / ml) Using a medium, a human neuroblastoma cell line SH-SY5Y cell (ATCCCRL-2266) was seeded at a concentration of 1.6 ⁇ 10 5 cells / ml on a 96-well plate coated with collagen ( ⁇ / ml).
- the vertical axis in FIG. 1 shows the number of surviving cells (quantitative protein value) in the sample-added group versus the number of surviving cells (quantitative protein value) in the sample-free group, and indicates the relative survival rate. That is, a value greater than 1.0 indicates that the survival rate is higher than that of the group without the sample.
- the horizontal axis represents the concentration of sampnore used.
- sucrose fatty acid ester 5 parts by weight of sucrose fatty acid ester
- the above composition was mixed and tableted to produce a dietary tablet containing a wolfberry plant material extract.
- a food and drink power capsule was manufactured.
- Soft flour 1 20 parts by weight
- a wolfberry plant material extract-containing cracker having the above composition was prepared by a conventional method.
- a dressing containing the wolfberry plant material extract was prepared by the usual method with the above composition.
- a chewing gum containing wolfberry plant material extract was prepared with the above composition by a conventional method.
- Extract of wolfberry extract material (Production Example 2) Dissolve an appropriate amount in hot water Industrial applicability
- the wolfberry plant material extract described herein is useful for preventing and / or ameliorating cerebral nerve cell death or preventing and / or improving Alzheimer's disease. Since the extract of wolfberry plant material of the present invention is highly safe and can be prepared by a simple method, the extract is expected to be extremely applicable to pharmaceuticals, foods and drinks, and to have a very wide range of application. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005513257A JPWO2005018656A1 (ja) | 2003-08-21 | 2004-07-27 | 脳神経細胞死予防及び/または改善剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-208138 | 2003-08-21 | ||
| JP2003208138 | 2003-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005018656A1 true WO2005018656A1 (ja) | 2005-03-03 |
Family
ID=34208962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/011037 Ceased WO2005018656A1 (ja) | 2003-08-21 | 2004-07-27 | 脳神経細胞死予防及び/または改善剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2005018656A1 (ja) |
| WO (1) | WO2005018656A1 (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2036568A1 (en) * | 2007-09-12 | 2009-03-18 | Nestec S.A. | Wolfberries and inflammation |
| JP2011529881A (ja) * | 2008-07-30 | 2011-12-15 | ネステク ソシエテ アノニム | 虚血及び虚血様状態に起因する損傷を予防、緩和又は治療するための方法及び組成物 |
| JP2013209354A (ja) * | 2012-02-29 | 2013-10-10 | Kanpo Ikagaku Kenkyusho:Kk | 認知機能低下改善用組成物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001322944A (ja) * | 2000-05-16 | 2001-11-20 | Kokusai Kanpo Kenkyusho:Kk | 漢方健康飲料およびこれに用いる抽出処理方法 |
-
2004
- 2004-07-27 WO PCT/JP2004/011037 patent/WO2005018656A1/ja not_active Ceased
- 2004-07-27 JP JP2005513257A patent/JPWO2005018656A1/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001322944A (ja) * | 2000-05-16 | 2001-11-20 | Kokusai Kanpo Kenkyusho:Kk | 漢方健康飲料およびこれに用いる抽出処理方法 |
Non-Patent Citations (4)
| Title |
|---|
| ARCHIVES OF PHARMACOL. RESEARCH, vol. 14, no. 4, 1991, pages 325 - 329 * |
| DATABASE EMBASE [online] PARK M.J. ET AL.: "Effects of Lycii fructus on primary cultured chicken brain cells", XP002985684, Database accession no. 93119856 * |
| GEN ENJUN ET AL.: "Chugoku ni okeru chihosho kenkyu", CLINICAL JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 20, no. 4, pages 383 - 386, XP002985683 * |
| OISHI M. ET AL.: "Effectiveness of traditional chinese medicine in Alzheimer disease", ALZHEIMER DISEASE AND ASSOCIATED DISORDERS, vol. 12, no. 3, 1998, pages 247 - 250, XP002985682 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2036568A1 (en) * | 2007-09-12 | 2009-03-18 | Nestec S.A. | Wolfberries and inflammation |
| WO2009034162A1 (en) * | 2007-09-12 | 2009-03-19 | Nestec S.A. | Wolfberries and inflammation |
| RU2499604C2 (ru) * | 2007-09-12 | 2013-11-27 | Нестек С.А. | Заманиха и воспаление |
| US9072769B2 (en) | 2007-09-12 | 2015-07-07 | Nestec S.A. | Wolfberries and skin inflammation |
| JP2011529881A (ja) * | 2008-07-30 | 2011-12-15 | ネステク ソシエテ アノニム | 虚血及び虚血様状態に起因する損傷を予防、緩和又は治療するための方法及び組成物 |
| JP2013209354A (ja) * | 2012-02-29 | 2013-10-10 | Kanpo Ikagaku Kenkyusho:Kk | 認知機能低下改善用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2005018656A1 (ja) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5300167B2 (ja) | 気分障害治療用組成物 | |
| KR20170113447A (ko) | 줄기세포 추출물을 포함하는 염증성 질환의 예방 또는 치료효과를 갖는 약학 조성물 | |
| US7914825B2 (en) | Encapsulated vaccinium extracts with balanced gastrointestinal release | |
| KR20090050295A (ko) | 해방풍 추출물을 유효성분으로 함유하는 부종 또는 피부염예방 및 치료용 조성물 | |
| KR101320738B1 (ko) | 미세조류 유래 색소를 추출하는 방법 및 추출된 푸코크산틴을 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물 | |
| KR101734896B1 (ko) | 감나무 추출물을 유효성분으로 포함하는 각막 손상의 예방, 개선 또는 치료용 조성물 | |
| JP2008531584A (ja) | マタタビ属を含む組成物およびそれを用いる方法 | |
| KR101584431B1 (ko) | 달맞이꽃 추출물을 유효성분으로 함유하는 미소중력하 또는 신경손상으로 인한 근위축 예방 또는 치료용 약학 조성물 | |
| JP5508656B2 (ja) | 最終糖化産物生成阻害組成物 | |
| KR102428082B1 (ko) | 항염증 면역활성 및 항산화 활성을 가지며, 노인의 근력 또는 근육 강화를 위한 근세포 조성에 우수한 효과를 제공하는 프테로카리아 스테놉테라 추출물을 포함하는 화장료 조성물, 약학적 조성물, 및 식품 조성물 | |
| JP2007084504A (ja) | 大麦を発酵に付したものを有効成分とする血管新生阻害の作用を有する組成物 | |
| WO2005018656A1 (ja) | 脳神経細胞死予防及び/または改善剤 | |
| JP2023501136A (ja) | クルクミノイド及び甘草抽出物またはその分画物を含有するブタ流行性下痢ウイルス感染の予防または治療用組成物 | |
| KR101838142B1 (ko) | 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물 | |
| JP2005179285A (ja) | ヒスタミン遊離抑制剤及びそれを含む飲食品 | |
| KR101732146B1 (ko) | 옥수수수염 및 탱자 복합추출물을 함유하는 항비만용 조성물 | |
| KR101392333B1 (ko) | 로도덴드론 알붐 추출물 또는 이의 분획물을 함유하는 염증성 질환의 예방 및 치료를 위한 약학적 조성물 | |
| CA3217764A1 (en) | Method for treating non-alcoholic steatohepatitis through co-administration of curcumin derivative and tgf-b receptor inhibitor | |
| EP3210602B1 (en) | Composition for preventing or treating neurodegenerative diseases, containing ramalin | |
| TWI917530B (zh) | 含有螺旋藻酶解物及/或藻藍蛋白酶解物的組成物用於製備提高記憶學習功能及/或認知功能以及抑制記憶學習功能及/或認知功能降低的組成物的用途 | |
| WO2005092357A1 (ja) | 抗アレルギー剤および抗炎症剤 | |
| KR102857817B1 (ko) | 발효 보리종자 추출물을 포함하는 세포노화 관련 질환 예방 또는 치료용 조성물 | |
| JP2006028091A (ja) | 脳機能改善組成物 | |
| JP6115995B2 (ja) | 非酵素的糖化反応抑制剤 | |
| EP4464175A1 (en) | Composition for improving memory or cognition or preventing or treating cranial nerve diseases, comprising porcine brain hydrolysates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2005513257 Country of ref document: JP |
|
| 122 | Ep: pct application non-entry in european phase |